Evidence map›Paper›PMID 22745608›Full record

ArticlePLoS medicine2012

Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples.

Craig R Cohen, Jairam R Lingappa, Jared M Baeten, Musa O Ngayo, Carol A Spiegel, Ting Hong, Deborah Donnell, Connie Celum, Saidi Kapiga, Sinead Delany and 1 more

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 217 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
217citing papers in PubMed, 3 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00194519 phase3completednot on this map

Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples

TypeinterventionalSponsorUniversity of WashingtonRan2004 to 2010Enrolled3,408ConditionsHIV Infection, Herpes Simplex, Genital, Sexually Transmitted DiseasesArmsGeneric acyclovir, Placebo
NCT02432404 phase4completednot on this mapstarted 2016, after this paper: background citation

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

TypeinterventionalSponsorUniversity of WashingtonRan2016 to 2021Enrolled81ConditionsBacterial VaginosisArmsNuvaRing
NCT02445989 phase4completednot on this mapstarted 2016, after this paper: background citation

Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity

TypeinterventionalSponsorUniversity of WashingtonRan2016 to 2018Enrolled120ConditionsBacterial Vaginosis, HIVArmsNuvaRing
3 · Its place in the literature

Who cites it

217 citing papers in PubMed, 3 syntheses or guidelines pooled it, 374 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Sexually transmitted diseases treatment guidelines, 2015.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2015
    Guideline
  4. Trial
  5. Trial
  6. Orally administratedFrontiers in immunology · 2023
    Trial
  7. Trial
  8. ProbioticFrontiers in cellular and infection microbiology · 2021
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Improvement of abnormal vaginal flora in Ugandan women by self-testing and short use of intravaginal antimicrobials.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Trial
  18. Trial
  19. Trial
  20. Trial

157 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Craig R CohenDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, United States of America. ccohen@globalhealth.ucsf.edu
Jairam R Lingappa
Jared M Baeten
Musa O Ngayo
Carol A Spiegel
Ting Hong
Deborah Donnell
Connie Celum
Saidi Kapiga
Sinead Delany
Elizabeth A Bukusi
University of Washington · USUniversity of California, San Francisco · USFred Hutch Cancer Center · USKenya Medical Research Institute · KELondon School of Hygiene & Tropical Medicine · GBUniversity of the Witwatersrand · ZAUniversity of Wisconsin–Madison · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Viral Determinants of HIV-1 Transmission in African HeterosexualsP01AI057005 · NIAID · UNIVERSITY OF WASHINGTON · PI COREY, LAWRENCE · 2003 to 2014
$20.5M
Multi-component, Targeted HIV Prevention for sub-Saharan Africa: PreventionRxR01AI083034 · NIAID · UNIVERSITY OF WASHINGTON · PI CELUM, CONNIE L · 2009 to 2012
$4.3M
NIAID NIH HHS P01 AI057005NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI-083034NIAID NIH HHS R01 AI083034
6 · The paper itself

Abstract

backgroundBacterial vaginosis (BV), a disruption of the normal vaginal flora, has been associated with a 60% increased risk of HIV-1 acquisition in women and higher concentration of HIV-1 RNA in the genital tract of HIV-1-infected women. However, whether BV, which is present in up to half of African HIV-1-infected women, is associated with an increase in HIV-1 transmission to male partners has not been assessed in previous studies. METHODS AND

findingsWe assessed the association between BV on female-to-male HIV-1 transmission risk in a prospective study of 2,236 HIV-1-seropositive women and their HIV-1 uninfected male partners from seven African countries from a randomized placebo-controlled trial that enrolled heterosexual African adults who were seropositive for both HIV-1 and herpes simplex virus (HSV)-2, and their HIV-1-seronegative partners. Participants were followed for up to 24 months; every three months, vaginal swabs were obtained from female partners for Gram stain and male partners were tested for HIV-1. BV and normal vaginal flora were defined as a Nugent score of 7-10 and 0-3, respectively. To reduce misclassification, HIV-1 sequence analysis of viruses from seroconverters and their partners was performed to determine linkage of HIV-1 transmissions. Overall, 50 incident HIV-1 infections occurred in men in which the HIV-1-infected female partner had an evaluable vaginal Gram stain. HIV-1 incidence in men whose HIV-1-infected female partners had BV was 2.91 versus 0.76 per 100 person-years in men whose female partners had normal vaginal flora (hazard ratio 3.62, 95% CI 1.74-7.52). After controlling for sociodemographic factors, sexual behavior, male circumcision, sexually transmitted infections, pregnancy, and plasma HIV-1 RNA levels in female partners, BV was associated with a greater than 3-fold increased risk of female-to-male HIV-1 transmission (adjusted hazard ratio 3.17, 95% CI 1.37-7.33).

conclusionsThis study identified an association between BV and increased risk of HIV-1 transmission to male partners. Several limitations may affect the generalizability of our results including: all participants underwent couples HIV counseling and testing and enrolled in an HIV-1 prevention trial, and index participants had a baseline CD4 count ≥ 250 cells/mm³ and were HSV-2 seropositive. Given the high prevalence of BV and the association of BV with increased risk of both female HIV-1 acquisition and transmission found in our study, if this association proves to be causal, BV could be responsible for a substantial proportion of new HIV-1 infections in Africa. Normalization of vaginal flora in HIV-1-infected women could mitigate female-to-male HIV-1 transmission.

trial registrationClinicalTrials.com NCT00194519.

Indexed as

Family CharacteristicsAdultAfricaClinical Trials as TopicCohort StudiesFemaleHIV-1HIV InfectionsHIV SeropositivityHumansIncidenceMaleProspective StudiesRisk FactorsRNA, ViralVaginaRNA, Viral

Identifiers

PMID22745608
PMCPMC3383741
OpenAlexW2027378590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.